MPS IIIA

Immunology

5 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

BLA Filed(1)

Drug	Company
UX111 (ABO-102)	ABEONA THERAPEUTICS INC. (ABEO)

Phase 2/Phase 3(4)

Drug	Company
Adjuvant IM Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
Optimized Prophylactic IM Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
Prophylactic Immunomodulatory Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
UX111	Ultragenyx Pharmaceutical Inc. (RARE)

BioSniper tracks 5 drugs in development for MPS IIIA across 2 companies.

There are 2 clinical trials targeting MPS IIIA tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.